- Audited results for the year ended 31 Dec 2023
- Business Update for Q1 2024
- Notice of Results
- Unaudited Full Year Trading Update
- Appointment of new Chief Financial Officer
- Q3 2023 U.S. Commercial Highlights
- PDMR Transaction Notification
- Abstract to be presented at Healthcare Conference
- Chief Financial Officer Transition
- Result of REX Retail Offer
More ▼
Key statistics
On Wednesday, Shield Therapeutics PLC (STX:LSE) closed at 2.05, 92.94% above the 52 week low of 1.06 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.93 |
---|---|
High | 1.97 |
Low | 1.97 |
Bid | 2.00 |
Offer | 2.30 |
Previous close | 2.05 |
Average volume | 4.16m |
---|---|
Shares outstanding | 782.06m |
Free float | 342.71m |
P/E (TTM) | -- |
Market cap | 15.05m GBP |
EPS (TTM) | -0.0458 GBP |
Data delayed at least 20 minutes, as of May 22 2024 16:38 BST.
More ▼
Investors Chronicle View
The last IC recommendation on Shield Therapeutics PLC shares was Hold at 155.00 on 08 Aug 2019Read the full article